107 related articles for article (PubMed ID: 10571663)
1. Immunotherapy of disseminated fibrosarcoma in mice using IL-2-producing tumor cells: studies on its mechanism and specificity.
Tsukada H; Yoshizawa H; Takeda T; Ohno K; Ichikawa K; Suzuki Y; Suzuki E; Wei ZG; Arakawa M; Gejyo F
Cancer Detect Prev; 1999; 23(6):524-33. PubMed ID: 10571663
[TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
3. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.
Shimizu K; Fields RC; Giedlin M; Mulé JJ
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2268-73. PubMed ID: 10051630
[TBL] [Abstract][Full Text] [Related]
4. Genetic immunotherapy by intrapleural, intraperitoneal and subcutaneous injection of IL-2 gene-modified Lewis lung carcinoma cells.
Heike Y; Takahashi M; Ohira T; Naruse I; Hama S; Ohe Y; Kasai T; Fukumoto H; Olsen KJ; Podack EE; Saijo N
Int J Cancer; 1997 Dec; 73(6):844-9. PubMed ID: 9399664
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2.
Bubeník J; Símová J; Jandlová T
Immunol Lett; 1990 Feb; 23(4):287-92. PubMed ID: 2347603
[TBL] [Abstract][Full Text] [Related]
6. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
7. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor.
Karp SE; Farber A; Salo JC; Hwu P; Jaffe G; Asher AL; Shiloni E; Restifo NP; Mulé JJ; Rosenberg SA
J Immunol; 1993 Feb; 150(3):896-908. PubMed ID: 8423345
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of pulmonary metastases using monoclonal antibody to T-cell suppressor factor and interleukin 2.
Kim B; Warnaka P; Iverson M; Imbembo AL
Arch Surg; 1987 Dec; 122(12):1455-9. PubMed ID: 3500692
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells.
Mitsuma S; Yoshizawa H; Ito K; Moriyama H; Wakabayashi M; Chou T; Arakawa M; Shu S
Immunology; 1994 Sep; 83(1):45-51. PubMed ID: 7821965
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
11. Insertion of the IL-2 gene decreases tumorigenicity of murine fibrosarcoma.
Kuśnierczyk H; Załecki P; Pajtasz-Piasecka E; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1998; 46(4):259-65. PubMed ID: 9779293
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors.
Chou T; Bertera S; Chang AE; Shu S
J Immunol; 1988 Sep; 141(5):1775-81. PubMed ID: 3261761
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
14. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
[TBL] [Abstract][Full Text] [Related]
15. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice.
Hirahara N; Nio Y; Sasaki S; Minari Y; Takamura M; Iguchi C; Dong M; Yamasawa K; Tamura K
Oncology; 2001; 61(1):79-89. PubMed ID: 11474253
[TBL] [Abstract][Full Text] [Related]
16. Donor cell cycling, trafficking, and accumulation during adoptive immunotherapy for murine lung metastases.
Skitzki J; Craig RA; Okuyama R; Knibbs RN; McDonagh K; Chang AE; Stoolman LM
Cancer Res; 2004 Mar; 64(6):2183-91. PubMed ID: 15026361
[TBL] [Abstract][Full Text] [Related]
17. Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells.
Sadanaga N; Nagoshi M; Lederer JA; Joo HG; Eberlein TJ; Goedegebuure PS
J Immunother; 1999 Jul; 22(4):315-23. PubMed ID: 10404433
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
19. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
[TBL] [Abstract][Full Text] [Related]
20. A single intratumoral injection of a fiber-mutant adenoviral vector encoding interleukin 12 induces remarkable anti-tumor and anti-metastatic activity in mice with Meth-A fibrosarcoma.
Gao JQ; Sugita T; Kanagawa N; Iida K; Eto Y; Motomura Y; Mizuguchi H; Tsutsumi Y; Hayakawa T; Mayumi T; Nakagawa S
Biochem Biophys Res Commun; 2005 Mar; 328(4):1043-50. PubMed ID: 15707983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
